Filter posts

ICYMI: A Bipartisan Drug Cartel?

“As false as it is implausible.” That’s how a Wall Street Journal editorial describes a …

FDA’s Historic Gene Therapy Approvals Could Be Beginning of the End of Blood Cancer

In his inaugural address this June as chairman of the world’s largest biotechnology industry group, …

Finger Pointing Won’t Solve the Opioid Crisis. Innovation Will

In his column, the New York Times’s Nicholas Kristof’s does a disservice to the millions of …

Blaming Pharma Won’t Lower Health Care Costs

This week, the USA Today Editorial Board took aim at the pharmaceutical industry in a new piece: Stop …

#BIF17: Looking Ahead to 2018 Policy Landscape

The past year has seen a number of important changes in the legislative and policy …

#BIF17: Turning the Tide on Antimicrobial Resistance

It’s no secret that antimicrobial resistance (AMR) is one of the most serious public health …

For Today’s Hearing on the Drug Delivery System, ‘Follow The Pill’

The Senate Committee on Health, Education, Labor, and Pensions will hold a hearing this morning …

New Infographic: The Bayh-Dole Act

$1.3 trillion in economic output. Support for roughly 4.2 million jobs. The creation of more …

ICYMI: Jim Greenwood Weighs In on the Future of Drug Pricing

Rewarding for quality – not quantity – is becoming more and more common in health …

ICYMI: Drug Development is Complicated. Let’s Start with the Facts.

Here’s a fact you might not have known: 90% of drug development programs fail. Yet …